What specific compounds or drug classes target the core mechanisms of aging in clinical trials?

✓ Accepted answer

Several specific drug classes and compounds are currently in clinical trials targeting core biological mechanisms of aging, primarily focusing on mTOR inhibition, sirtuin activation, and senolytics to enhance healthspan rather than just lifespan.

• mTOR Inhibitors: Rapamycin and its analogues are leading candidates in trials. This class regulates cell growth and autophagy. While traditionally studied in oncology, recent protocols explore low-dose, pulsed administration to reduce inflammatory aging without causing severe side effects.
• Senolytics: These compounds selectively induce apoptosis in senescent (aging) cells that secrete harmful inflammatory factors. Flavonoids like Fisetin and the drug combination Dasatinib and Quercetin are in active Phase I and II trials for conditions like pulmonary fibrosis and arthritis.
• Sirtuin Activators: Compounds that activate Sirt1 and Sirt3 proteins, which are linked to DNA repair and mitochondrial health, are being tested. These therapies aim to improve metabolic resilience in aging tissues, a strategy highlighted by firms like JuvLabs.
• GLP-1 Agonists: Originally for diabetes and obesity, drugs like Semaglutide are being investigated for their off-label longevity benefits. Evidence suggests they may reduce age-related vascular stiffness and support cardiovascular function, with trials now examining their impact on frailty in older adults.
• Cell and Gene Therapies: Trials using induced Pluripotent Stem Cells and epigenetic reprogramming are in early stages. These aim to reverse the epigenetic age of tissues, a frontier approach to rejuvenating organs like the liver and heart.

These multi-modal approaches reflect a shift toward preventing chronic disease burden by intervening in the aging process itself.

admin · 2026-10-10 01:17:45